Cabot (CBT) Up 4.4% Since Last Earnings Report: Can It Continue?
Cabot (CBT) reported earnings 30 days ago. What's next for the stock?
Is the Options Market Predicting a Spike in Cabot Stock?
Investors need to pay close attention to Cabot stock based on the movements in the options market lately.
Is It Time To Buy Cabot Stock?
Cabot (CBT) hasn't been in the spotlight lately, but its current setup may warrant a closer look. The specialty chemicals company has quietly built a strong financial base while its stock remains meaningfully discounted from recent highs.
Cabot's Q4 Earnings and Sales Miss Estimates, Decline Y/Y
CBT's Q4 earnings miss estimates as weaker demand and volumes weighed on sales.
Cabot: The Decline Now Sees Valuation Making Sense (Rating Upgrade)
Cabot Corporation is a fundamentally strong, conservatively managed chemical company trading at a significant discount to fair value. CBT offers high single-digit growth, a well-covered dividend, and is positioned for long-term upside despite recent market-driven declines. Recent results show resilience in key segments and strategic expansion, with risks mainly tied to macro volatility and market sentiment.
CBT Boosts North American Capacity of Circular Reinforcing Carbons
Cabot boosts its North American capacity to produce sustainable circular reinforcing carbons, advancing its EVOLVE platform and regional manufacturing strategy.
Why Is Cabot (CBT) Up 0.9% Since Last Earnings Report?
Cabot (CBT) reported earnings 30 days ago. What's next for the stock?
Cabot's Earnings Top Estimates in Q3, Sales Miss on Lower Volumes
Cabot beats Q3 profit forecasts despite lower volumes, with strong cash flow and reaffirmed 2025 earnings guidance.
Cabot Corporation (CBT) Q3 2025 Earnings Call Transcript
Cabot Corporation (NYSE:CBT ) Q3 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Erica J. McLaughlin - Executive VP, CFO & Head of Corporate Strategy Sean D.
Cabot (CBT) Q3 Earnings Surpass Estimates
Cabot (CBT) came out with quarterly earnings of $1.9 per share, beating the Zacks Consensus Estimate of $1.8 per share. This compares to earnings of $1.92 per share a year ago.
Cabot: An Interesting Specialty Chemical Play
Cabot Corp. trades at just 10x earnings despite a solid track record, reasonable leverage, and high margins, making the valuation look attractive. Recent weakness in reinforcement materials and tariff uncertainty led to a guidance cut, but performance chemicals and semiconductor demand remain bright spots as the overall results come in flattish. Capital investments and buybacks have increased leverage modestly, but the balance sheet remains healthy and the dividend yield is near 2.5%.
Why Is Cabot (CBT) Up 3.9% Since Last Earnings Report?
Cabot (CBT) reported earnings 30 days ago. What's next for the stock?
